At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 347 enrolled
Drug / intervention
Mepolizumabdrug
Likely dose
Mepolizumab 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 Trial
In Brief
A Phase 3 clinical trial evaluating Mepolizumab for Asthma. Completed, enrolled 347 participants across 64 sites in 13 countries.
Detailed Summary
This is a multi-centre, open-label long term safety study of 100 milligrams (mg) mepolizumab administered subcutaneously (SC) in addition to standard of care in subjects who participated in the MEA112997 study. At each clinic visit, adverse events will be assessed and exacerbations will also be reviewed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesArgentina, Australia, Canada, Chile, France, Germany, Poland, Romania, Russia, South Korea, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartSep 2012
Primary CompletionMay 2017
TodayJul 2026
First PostedSep 25, 2012
Enrollment StartSep 28, 2012
Primary CompletionMay 31, 2017
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 13.8 years ago
Interventions
Mepolizumabdrug
100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks